Long COVID: Scale, Definition, and Clinical Scope
Long COVID — also termed post-acute sequelae of SARS-CoV-2 (PASC), post-COVID condition, or post-COVID syndrome — is defined by the WHO as "the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation." It affects an estimated 10–20% of people infected with SARS-CoV-2, representing tens of millions of individuals globally as of 2026. The most prevalent symptoms are fatigue (present in ~70% of long COVID patients), cognitive impairment or 'brain fog' (~50%), post-exertional malaise (~50%), dyspnoea (~35%), and a diverse spectrum of neurological, cardiac, gastrointestinal, and musculoskeletal symptoms.
The clinical heterogeneity of long COVID has made unified mechanistic understanding difficult, but several pathophysiological threads have emerged from converging research streams: viral persistence, immune dysregulation, microbiome disruption, reactivation of latent viruses (particularly EBV), autonomic nervous system dysfunction, and — the focus of this article — mitochondrial dysfunction. These mechanisms are not mutually exclusive; they likely coexist and interact in different patient subgroups.
The Evidence for Mitochondrial Dysfunction
The most direct evidence for mitochondrial pathology in long COVID comes from skeletal muscle biopsy studies. The 2022 Appelman et al. study (Nature Communications) biopsied vastus lateralis muscle in 25 long COVID patients with post-exertional fatigue and 21 healthy controls, using electron microscopy, proteomics, and respiratory complex activity assays. Key findings: mitochondrial ultrastructural abnormalities (disrupted cristae morphology, reduced mitochondrial area, increased lipid droplet accumulation within fibres), reduced complex I and III activity, increased muscle inflammation, and altered metabolomics consistent with impaired beta-oxidation. These are objective, biopsy-confirmed findings — not self-report — establishing mitochondrial pathology as a histological reality in this patient subgroup.
Complementary evidence from metabolomics: multiple independent untargeted metabolomics studies of long COVID patient plasma find a consistent signature of mitochondrial impairment — reduced carnitine and acylcarnitine species (impaired fatty acid transport into mitochondria), reduced CoQ10, reduced NAD+/NADH ratio, elevated oxidative stress markers, and reduced TCA cycle intermediates (succinate, fumarate, citrate) consistent with reduced TCA cycle flux. Cardiopulmonary exercise testing (CPET) in long COVID consistently demonstrates reduced VO2max, earlier anaerobic threshold, and elevated ventilatory equivalent for CO2 — a pattern consistent with mitochondrial oxidative capacity limitation rather than cardiac or ventilatory pathology.
Persistent Viral Fragments and Immune Dysregulation
Several lines of evidence suggest that SARS-CoV-2 components persist in body tissues beyond the acute phase of infection. PCR detection of viral RNA in gut biopsies months after recovery, detection of spike protein in circulating monocytes, and viral nucleocapsid in post-mortem tissue samples (including lymph nodes and brain) have been reported. Whether these represent replication-competent virus or non-replicating fragments is actively debated, but even non-replicating viral antigens can maintain immune activation through pattern recognition receptor signalling.
The immune dysregulation in long COVID is well-documented: reduced numbers of regulatory T cells (Tregs), elevated cytotoxic T cell activation, elevated IFN-γ signalling, and autoantibody production (anti-phospholipid antibodies, anti-ACE2 antibodies, anti-β2-adrenergic receptor antibodies — the latter potentially explaining the autonomic dysfunction and POTS) are among the most replicated immune findings. This persistent immune activation drives ongoing inflammation that compounds the metabolic and mitochondrial dysfunction.
The ME/CFS Parallel and What It Teaches
The profound similarity between long COVID and ME/CFS is the most clinically important contextual insight for treatment. ME/CFS has been studied for over three decades, producing: (1) the critical finding that graded exercise therapy (GET) harms patients with PEM through a mechanism of mitochondrial crisis — pushing beyond the anaerobic threshold produces oxidative damage that exceeds mitochondrial repair capacity; (2) pacing and energy envelope management as the primary safe rehabilitation strategy; (3) POTS as a common underlying driver of fatigue and cognitive symptoms that responds to specific treatment; and (4) LDN as the most consistently promising pharmacological intervention in multiple pilot trials.
The two-day CPET protocol developed by Workwell Foundation (Vanness, Stevens) — showing objective physiological deterioration on day 2 testing in ME/CFS compared to healthy controls — provides the most compelling objective evidence that PEM is not psychological but represents real, measurable mitochondrial/metabolic impairment triggered by exertion.
Mitochondrial Support Interventions
Based on the metabolomics findings and mechanistic understanding, several targeted nutritional interventions are used in long COVID protocols, though most evidence is currently from small trials, case series, and mechanistic studies:
- CoQ10 (200–400mg/day ubiquinol) — directly supports ETC function; documented depletion in long COVID; pilot RCT evidence for fatigue improvement
- NAC (600–1200mg/day) — glutathione precursor, reduces mitochondrial ROS; mechanistic evidence from in vitro studies
- Alpha-lipoic acid (600mg/day R-ALA) — mitochondria-specific antioxidant that regenerates CoQ10, vitamin C, vitamin E, and glutathione
- L-carnitine/Acetyl-L-carnitine (1.5–3g/day) — documented depletion in long COVID; essential for mitochondrial fatty acid transport; ALCAR crosses the blood-brain barrier
- B vitamins (especially B1, B2, B3/NMN, B5) — all are essential cofactors in TCA cycle and ETC reactions; NAD+ precursors (NMN, NR) support NAD+ repletion in a condition of documented NAD+ depletion
- Magnesium glycinate (400mg/day) — essential cofactor in over 300 enzymatic reactions including ATP synthesis
The evidence quality for these interventions warrants honest framing. Most of the approaches listed above have supportive mechanistic rationale and small pilot study evidence in ME/CFS or long COVID, but lack large randomized controlled trials for this specific indication. CoQ10 and PQQ have the strongest mitochondrial evidence base overall — CoQ10 in particular has multiple small RCTs in chronic fatigue conditions showing fatigue improvement. NAD+ precursors (NMN and NR) have strong animal data and emerging human trial data showing NAD+ repletion is achievable, though functional outcomes in long COVID specifically await larger trials. The absence of large RCTs does not mean these interventions lack promise — it reflects that long COVID has only existed since 2020 and the research infrastructure to conduct adequately powered trials is still being established. Practitioners applying this framework should monitor response systematically using validated tools (fatigue severity scales, HRV tracking, Montreal Cognitive Assessment for brain fog) and treat each case as an n-of-1 trial, adjusting the protocol based on observed individual response rather than assuming uniform benefit across patients. The combination of low risk, strong mechanistic rationale, and preliminary positive signals makes systematic nutritional support a reasonable bridge intervention while the RCT evidence matures.
Pacing: The Non-Negotiable Foundation
For long COVID patients with PEM, pacing is not optional — it is the foundation upon which all other recovery strategies build. Heart rate monitoring during activity (target: staying below 60–70% of age-predicted maximum heart rate, or more precisely below the anaerobic threshold identified by CPET) prevents the energy crashes that maintain the illness. The Pacing, Graded Activity, and Cognitive Behavior Therapy (PACE) trial controversy in ME/CFS — where GET and CBT produced temporary symptom improvement but long-term harm in many participants — was a critical lesson: do not push patients with PEM to exert beyond their current capacity.
The Workwell Foundation's heart rate-guided pacing protocol provides the most operationalised approach: using heart rate monitoring continuously during all activity, establishing a personal anaerobic threshold (typically identified by CPET or estimated as 50–60% of maximum heart rate in severely ill patients), and building all activity budgets around staying consistently below this threshold. This means fragmenting activities into short blocks with rest between them, managing cognitive exertion (which consumes as much mitochondrial ATP as physical exertion), and rigorously prioritising sleep and rest as active recovery interventions. For many patients, strict pacing for 3–6 months produces gradual functional improvement as mitochondrial repair mechanisms operate without being overwhelmed by exercise-induced oxidative stress. The critical mistake is interpreting a period of improved function as recovery and dramatically increasing activity — the resulting PEM crash can set back recovery by months.
Orthostatic intolerance (POTS — postural orthostatic tachycardia syndrome) is present in approximately 30% of long COVID patients and is frequently under-recognised as a driver of fatigue and cognitive symptoms. Simple interventions — increased salt and fluid intake (2–3g sodium/day, 2–3L fluid/day), compression garments, and head-of-bed elevation — significantly reduce POTS symptoms for many patients. Pharmacological treatment (fludrocortisone, midodrine, propranolol, ivabradine) may be needed in severe cases. Treating POTS before attempting any physical rehabilitation is essential — orthostatic instability produces a state of chronic physiological stress that prevents functional recovery regardless of other interventions.
Current Evidence Base and Recovery Protocol Framework
Ongoing RCTs of LDN (NCT05430360), anticoagulation (multiple trials), and mitochondria-targeting interventions represent the most important near-term evidence expected to arrive over 2025–2027. The RECOVER-VITAL trial of nirmatrelvir/ritonavir (Paxlovid) for long COVID specifically targets the viral persistence mechanism. The HEAL-COVID platform trials across the UK are evaluating multiple interventions simultaneously. Until RCT data matures, current evidence-based management integrates several parallel treatment streams.
The mitochondrial support protocol — based on documented metabolomics deficiencies — begins with CoQ10 (200–400mg/day ubiquinol with fat-containing meals), NAC (600–1,200mg/day), and either NMN or NR for NAD+ repletion (500–1,000mg/day), given the consistent finding of reduced NAD+/NADH ratio in long COVID metabolomics. Acetyl-L-carnitine (1.5–2g/day) addresses the documented carnitine depletion affecting mitochondrial fatty acid transport. Vitamin D optimisation (target 50–60 ng/mL), magnesium glycinate (400mg/day), and B-complex supplementation address the cofactor requirements of mitochondrial enzyme systems. These supplements have minimal risk and strong mechanistic rationale; they are supportive measures rather than disease-modifying treatments but may meaningfully improve energy availability during recovery.
For patients with prominent neurological symptoms (brain fog, cognitive dysfunction, headaches) unresponsive to pacing and nutritional support, a trial of LDN at 1.5–4.5mg/day is the most evidence-informed pharmacological approach currently available, with a compelling mechanism (TLR4 inhibition, microglial activation reduction), an excellent safety profile, and growing case series evidence. The combination of strict pacing, POTS management, mitochondrial nutritional support, and LDN represents the current practical standard of care offered by long COVID specialist clinics, pending the RCT results that will refine this approach over the next 2–3 years.